Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer

Milo Frattini, Cristina Ferrario, Paola Bressan, Debora Balestra, Loris De Cecco, Piera Mondellini, Italia Bongarzone, Paola Collini, Manuela Gariboldi, Silvana Pilotti, Marco A. Pierotti, Angela Greco

Research output: Contribution to journalArticle


Papillary thyroid carcinoma (PTC) is associated with RET and NTRK1 rearrangements and BRAF mutations. A series of 60 PTCs collected in a single center from Italian patients were histologically re-examined and subclassified as well differentiated or tall cell variant. The sample collection was analysed for the presence of all the reported PTC-associated genetic alterations through DNA or cDNA amplification, followed by automated sequencing. The analysis of exons 11 and 15 of BRAF gene revealed the T1796A (V599E) mutation in 32% of cases, and this alteration is significantly associated with PTC tall cell variant. Oncogenic rearrangements of RET and NTRK1 receptors were found in 33 and 5% of cases, respectively. No Ras mutations were detected. Overall, genetic alterations were detected in two-thirds of samples, and in no single case more than one mutational event was found simultaneously. Gene expression profiling of a subset of 31 tumors performed using cDNA microarray chips showed no strong differences in global gene expression among the different cases. However, a supervised analysis of the obtained data identified a subset of genes differentially expressed in tumors carrying BRAF mutation or RTK rearrangement.

Original languageEnglish
Pages (from-to)7436-7440
Number of pages5
Issue number44
Publication statusPublished - Sep 23 2004



  • BRAF mutation
  • Papillary thyroid cancer
  • RET and TRK rearrangement

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this